Benefit-Risk Assessment Using Number Needed to Treat and Number Needed to Harm for Time-to-Event Endpoints
被引:2
|
作者:
Ke, Chunlei
论文数: 0引用数: 0
h-index: 0
机构:
Amgen Inc, Global Biostat Sci, One Amgen Ctr Dr, Thousand Oaks, CA 91320 USAAmgen Inc, Global Biostat Sci, One Amgen Ctr Dr, Thousand Oaks, CA 91320 USA
Ke, Chunlei
[1
]
Jiang, Qi
论文数: 0引用数: 0
h-index: 0
机构:
Amgen Inc, Global Biostat Sci, One Amgen Ctr Dr, Thousand Oaks, CA 91320 USAAmgen Inc, Global Biostat Sci, One Amgen Ctr Dr, Thousand Oaks, CA 91320 USA
Jiang, Qi
[1
]
机构:
[1] Amgen Inc, Global Biostat Sci, One Amgen Ctr Dr, Thousand Oaks, CA 91320 USA
Additive hazards;
Benefit-risk assessment;
Clinical trial;
Number needed to harm;
Number needed to treat;
ADDITIVE HAZARDS MODEL;
NORMAL VARIABLES;
FAILURE;
RATIOS;
D O I:
10.1080/19466315.2016.1197849
中图分类号:
Q [生物科学];
学科分类号:
07 ;
0710 ;
09 ;
摘要:
Number needed to treat (NNT) is a useful measure to meaningfully translate the therapeutic effect of a drug to clinical practice. Time-to-event endpoints are commonly used in clinical trials. NNT has been extended to time-to-event endpoints, but these extensions have some limitations. In addition, NNT and number needed to harm (NNH) can be applied to provide useful information in support of benefit-risk assessment of a drug. In this article, we will first propose a hazard-based NNT using an additive hazards model. Estimation and inference procedures will be provided. Graphical methods and formal statistical tests will be proposed to evaluate the assumption of additivity. We will also discuss using NNT and NNH to facilitate benefit-risk decision making. Inference on the NNH and NNT ratio will be explored as well. The proposed methods will be illustrated with a real clinical trial dataset.
机构:
Inst Hlth Sci, Ctr Stat Med, Imperial Canc Res Grp, Med Stat Grp, Oxford OX3 7LF, EnglandInst Hlth Sci, Ctr Stat Med, Imperial Canc Res Grp, Med Stat Grp, Oxford OX3 7LF, England
Altman, DG
Andersen, PK
论文数: 0引用数: 0
h-index: 0
机构:Inst Hlth Sci, Ctr Stat Med, Imperial Canc Res Grp, Med Stat Grp, Oxford OX3 7LF, England
Andersen, PK
BRITISH MEDICAL JOURNAL,
1999,
319
(7223):
: 1492
-
1495
机构:
Idorsia Pharmaceut Ltd, Global Clin Dev & Med Affairs, Allschwil, Switzerland
Idorsia Pharmaceut Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, SwitzerlandIdorsia Pharmaceut Ltd, Global Clin Dev & Med Affairs, Allschwil, Switzerland
Chalet, Francois-Xavier
Luyet, Pierre-Philippe
论文数: 0引用数: 0
h-index: 0
机构:
Idorsia Pharmaceut Ltd, Global Clin Dev & Med Affairs, Allschwil, SwitzerlandIdorsia Pharmaceut Ltd, Global Clin Dev & Med Affairs, Allschwil, Switzerland
Luyet, Pierre-Philippe
Rabasa, Cristina
论文数: 0引用数: 0
h-index: 0
机构:
Idorsia Pharmaceut Ltd, Global Clin Dev & Med Affairs, Allschwil, SwitzerlandIdorsia Pharmaceut Ltd, Global Clin Dev & Med Affairs, Allschwil, Switzerland
Rabasa, Cristina
Vaillant, Cedric
论文数: 0引用数: 0
h-index: 0
机构:
Idorsia Pharmaceut Ltd, Global Clin Dev & Med Affairs, Allschwil, SwitzerlandIdorsia Pharmaceut Ltd, Global Clin Dev & Med Affairs, Allschwil, Switzerland
Vaillant, Cedric
Saskin, Paul
论文数: 0引用数: 0
h-index: 0
机构:
Idorsia Pharmaceut US Inc, Med Affairs US, Radnor, PA USAIdorsia Pharmaceut Ltd, Global Clin Dev & Med Affairs, Allschwil, Switzerland
Saskin, Paul
Ahuja, Ajay
论文数: 0引用数: 0
h-index: 0
机构:
Idorsia Pharmaceut US Inc, Med Affairs US, Radnor, PA USAIdorsia Pharmaceut Ltd, Global Clin Dev & Med Affairs, Allschwil, Switzerland
Ahuja, Ajay
Citrome, Leslie
论文数: 0引用数: 0
h-index: 0
机构:
New York Med Coll, Dept Psychiat & Behav Sci, Valhalla, NY USAIdorsia Pharmaceut Ltd, Global Clin Dev & Med Affairs, Allschwil, Switzerland